scholarly journals monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer

2016 ◽  
Vol 27 ◽  
pp. vi99 ◽  
Author(s):  
S.M. Tolaney ◽  
N. Bourayou ◽  
S. Goel ◽  
T. Forrester ◽  
F. André
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Standard Of Care ◽  
Advanced Breast ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer

The Breast ◽  
2013 ◽  
Vol 22 (4) ◽  
pp. 470-475 ◽  
Author(s):  
Matteo Clavarezza ◽  
Monica Turazza ◽  
Enrico Aitini ◽  
Silvana Saracchini ◽  
Ornella Garrone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Phase II open-label study of sunitinib in patients with advanced breast cancer

2012 ◽  
Vol 136 (3) ◽  
pp. 759-767 ◽  
Author(s):  
Denise A. Yardley ◽  
E. Claire Dees ◽  
Stephen D. Myers ◽  
Sherry Li ◽  
Paul Healey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Advanced Breast ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Abstract OT-32-01: A phase 2, open-label study of bintrafusp alfa monotherapy in patients withHMGA2-expressing triple-negative breast cancer

2021 ◽  
Author(s):  
Leisha A Emens ◽  
Margaret E. Gatti-Mays ◽  
Joyce O’Shaughnessy ◽  
Luc Dirix ◽  
Giovanni Faggioni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document